---
title: "Humacyte says FDA accepts IND for first-in-human CTEV CABG study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293928671.md"
description: "Humacyte announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human study of its coronary tissue-engineered vessel used in Coronary Artery Bypass Grafting (CABG). The Phase 2a trial is scheduled to begin this quarter, involving 10 adult patients. The study will assess primary patency at two months with follow-ups extending up to three years."
datetime: "2026-07-27T12:03:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293928671.md)
  - [en](https://longbridge.com/en/news/293928671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293928671.md)
generator: "portal-rs"
---

# Humacyte says FDA accepts IND for first-in-human CTEV CABG study

-   Humacyte secured FDA acceptance of its IND for a first-in-human study of its coronary tissue engineered vessel in CABG. \* Phase 2a trial set to start this quarter in 10 adult patients; primary patency check at two months, follow-up up to three years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788296) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year](https://longbridge.com/en/news/296352370.md)
- [Humacyte says Phase 3 V012 trial shows ATEV extends catheter-free dialysis time in women](https://longbridge.com/en/news/296784335.md)
- [CytoSorbents says real-world analysis shows 37% drop in severe bleeding with CytoSorb in urgent CABG patients on ticagrelor](https://longbridge.com/en/news/297777770.md)
- [Eledon submits FDA IND for tegoprubart islet cell transplant trial in type 1 diabetes](https://longbridge.com/en/news/297902220.md)
- [Builders FirstSource to host 2026 investor day webcast](https://longbridge.com/en/news/297954126.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**